Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

RSS icon
Video of Kendra Grubb discussing transcatheter tricuspid and mitral advancements at TCT 2023.

Key trends in transcatheter tricuspid and mitral valve technologies

The mitral valve has been an especially challenging target for transcatheter interventions, but there are reasons to think key breakthroughs are on the horizon. We talked to Kendra Grubb, MD, about this and other ongoing trends at TCT 2023. 

Kendra Grubb discusses TAVR vs SAVR and the most recent data to explain choices with patients.

TAVR or SAVR? Where things stand now, from a surgeon's perspective

Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis. 

Example of intravascular ultrasound (IVUS) shown as part of the multimodality imaging capability on the Fujifilm CVIS.

IVUS-guided PCI boosts 2-year survival, reduces need for bypass surgery

IVUS was especially effective when treating patients with a complex coronary anatomy, researchers found. 

Samir Kapadia, MD, Cleveland Clinic, explains the WATCH TAVR study results that combined LAAO with transcatheter aortic valve replacement at TCT 2023. #TCT2023 #TAVR #Watchman #LAAO

TAVR and LAAO at the same time? Samir Kapadia breaks down the WATCH-TAVR trial

Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview. 

Thumbnail

IVL gains higher level of reimbursement with one of biggest coding updates for PCI in decades

Intravascular lithotripsy therapy to break up calcified coronary lesions will now be reimbursed at a higher rate under new in-hospital codes the went into effect Oct. 1.

Robert Yeh, MD, explains the details of the AGENT IDE trial clinical trial results for the Agent drug-coated balloon vs plain angioplasty for in-stent restenosis at TCT 2023. #TCT #TCT2023 #DCB

Coronary drug-coated balloon superior to standard of care for in-stent restenosis

Robert Yeh, MD, detailed the importance of the pivotal AGENT IDE trial, which focused on the use of a paclitaxel-coated balloon to treat in-stent restenosis. 

Video of Michael Reardon, MD, explaining details from the Evolute Low Risk 4-year results at TCT 2023.

TAVR triumphs over surgery: Exploring 4-year data from the Evolut Low Risk trial

Michael Reardon, MD, discussed his team's late-breaking results at TCT 2023 in San Francisco. 

The Evoque transcatheter tricuspid valve replacement (TTVR) system for tricuspid regurgitation from Edwards Lifesciences

More good news for Edwards: ‘Landmark study’ confirms new TTVR system reduces tricuspid regurgitation, improves symptoms

New data presented at TCT 2023 suggest the Evoque tricuspid valve replacement system could make a significant impact on the lives of patients with severe TR. 

Displaying 33 - 40 of 123

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.